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Cardiac remodeling is frequently observed in patients with sickle cell disease (SCD), and 
contributes to cardiac dysfunction and premature death1, 2. Cardiac dysfunction in SCD has 
been related to chronic anaemia and low oxygen saturation, however the mechanisms 
whereby they induce cardiac dysfunction are incompletely understood and additional factors 
are still to be identified among which the fibroblast growth factor 23 (FGF23) is a potential 
candidate. FGF23 is secreted by bone cells and controls calcitriol and serum phosphate 
concentrations by acting on the kidney, which is its main physiologic target3. The intact form 
of FGF23 (iFGF23) mediates its physiologic effects. iFGF23 is the only form that circulates 
under physiological conditions. FGF23 can be cleaved in a N and a C-terminal fragments and 
it is uncertain if these fragments have any biological effects. Two different immunoassays 
allow the measurements of iFGF23 or C-terminal FGF23 fragment (cFGF23) concentrations. 
In patients with chronic kidney disease (CKD) plasma FGF23 concentration progressively 
increases when glomerular filtration rate (GFR) declines. Elevated FGF23 concentration has 
been associated with cardiac hypertrophy and mortality in CKD patients4 and in the general 
population5, 6. Data obtained in animals strongly suggest that iFGF23 can provoke deleterious 
effects on heart. Injection of iFGF23 in the heart of rats induces cardiac hypertrophy7. In 5/6 
nephrectomized rats, which have elevated iFGF23 plasma concentration, treatment with a 
FGF receptor (FGFR) antagonist attenuated cardiac hypertrophy. The mechanism whereby 
iFGF23 can induce heart hypertrophy is still incompletely understood but does not require the 
expression the FGF23 co-receptor αKlotho. To determine if FGF23 could participate to 
cardiac remodelling in SCD patients we measured plasma iFGF23 and cFGF23 
concentrations in 77 young adult SCD patients and 172 healthy control subjects of same 
ethnic background. The main characteristics of the SCD patients and the control subjects are 
presented in Online Supplementary Table S1. Among the SCD patients, 53 had haemoglobin 
SS genotype (HbSS), 15 had haemoglobin SC (HbSC), 8 had sickle cell haemoglobin S-β 
thalassemia (HbS β) and 1 had haemoglobin SD (HbSD). Patients with SCD were younger, 
had lower BMI, lower blood pressure, higher estimated GFR and lower haemoglobin 
concentration than controls. SCD patients had significantly higher cFGF23 plasma 
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concentration than controls whatever their phenotypes (SS or non-SS) (Figure1A). 58 
(75.3%) SCD patients, vs. 18 (10.5%) controls had values above normal (150 RU/ml) (p<10-
4). Patients with SS genotype had significantly higher cFGF23 concentration than non-SS 
patients (Figure1A). Forty-five of SS patients (86.5%) and 13 of non-SS patients (52%) had 
cFGF23 concentration above the upper normal value (p=0.0013). We also measured FGF23 
concentration with an assay that measures only iFGF23 in 50 SCD patients (33 with SS 
genotype and 17 with non SS genotype). In this subgroup cFGF23 concentration was above 
normal values in 39 patients (78%). By contrast iFGF23 concentration was normal 
(<50pg/ml) in all but 5 of these 50 SCD patients. Furthermore in SCD patients, at variance 
with what we observed in non-SCD subjects, iFGF23 and cFGF23 levels did not correlate 
(On line supplementary figure S1) suggesting that mainly cleaved FGF23 was present in the 
plasma of SCD patients. cFGF23 concentration correlated negatively with haemoglobin levels 
in SCD patients (r2=0.187, p<0.0001). We observed a negative correlation between 
haemoglobin levels and GFR (r2=0.062, p=0.0293) and a positive correlation between 
cFGF23 and GFR (r2=0.058, p= 0.0343). Serum phosphate concentration did not differ 
between SCD patients and controls (1.12±0.18 vs. 1.13±0.25 mmol/L p=0.7267). Calcitriol 
concentration did not correlate with cFGF23 concentration in SCD patients (r2=0.038, 
p=0.0925). All these findings reinforce the hypothesis that elevated FGF23 in SCD patients 
could reflect the presence of cleaved FGF23 rather than the intact form. 
We performed echocardiography in SCD patients and found that left ventricle mass index 
(LVMI) and Left ventricle end diastolic diameter (LVEDD) were increase in 68.8% and 
35.1% of SCD patients, respectively. Eight patients had E/E’ ratio > 8 which is considered as 
a good predictor of diastolic dysfunction (Online Supplementary Table S2). 
Univariate analysis showed that LVMI, LVEDD and LVESD correlated significantly and 
positively with cFGF23 concentration, GFR, and negatively with haemoglobin levels (Table 
1). These correlations were present in SS and non-SS patients. Left ventricular ejection 
fraction (FE) and fraction of shortening (FS) did not correlate with FGF23, GFR, or 
haemoglobin values. 
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In multivariate regression analysis the relationship between LVMI and cFGF23 remained 
significant after stepwise adjustment for haemoglobin and GFR (Table 2). After adjustment 
for GFR, LVEDD and LVESD no longer correlated with FGF23. 
To determine if cFGF23 could induce cardiac hypertrophy, we expressed the cDNA sequence 
encoding amino acids 178 to 251 of FGF23 in Chinese hamster ovary cells and produced a 
purified protein using the Myc-tag of the protein. We cultivated adult rat ventricular myocytes 
(ARVMs) for 24hrs in the presence of the purified cFGF23. As shown in figure 1B cFGF23 
significantly increased in a concentration dependent manner the cell surface area of ARVMs. 
This effect was similar to that observed with FGF2, a fibroblast growth factor known to 
induce cardiac hypertrophy. ARVMs, did not express αKlotho mRNA but expressed various 
types of FGFR in western blot experiments (data not shown). To determine if FGFR could 
mediate cFGF23-induced cardiomyocyte hypertrophy, ARVMs were incubated with cFGF23 
or FGF2 alone or in the presence of a FGFR inhibitor (PD166866 from Sigma-Aldrich). The 
FGFR inhibitor fully prevented both cFGF23 and FGF2 induced hypertrophy (Figure 1B). 
Treatment of ARVMs with cFGF23 also resulted in a significant increase in the beta myosin 
heavy chain mRNA expression, a marker of cardiac hypertrophy (online supplementary figure 
S2). 
Our results indicate that a cleaved form of FGF23 is released in the blood of SCD patients 
and demonstrate for the first time that cFGF23 can induce cardiac hypertrophy via activation 
of a FGF receptor and may contribute to the cardiac remodelling in SCD patients. The 
mechanisms leading to the release of cFGF23 in the plasma of SCD patients require further 
investigation, however we can make some hypotheses. cFGF23 correlated negatively with 
haemoglobin and positively with GFR, suggesting that cFGF23 concentration correlates with 
the consequences of the SCD, anaemia and glomerular hyperfiltration that is an early marker 
of SCD renal dysfunction8, 9. In the present study FGF23 elevation was not due to a decrease 
in GFR. Release of phosphate by haemolysis might have stimulated FGF23 release, however 
several data do not support this hypothesis: serum phosphate concentration was not different 
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between control and SCD patients and did not differ between SS and non-SS patients. Iron 
deficit or overload can modify FGF23 concentration10, 11. A role for iron status in SCD 
patients is unlikely since we found no association between FGF23 and iron, transferrin or 
ferritin concentrations. Anaemia induces tissue hypoxia that can stimulate cFGF23 production 
in mice12. Bone cells UMR-106 cultured under hypoxic conditions increased FGF23 mRNA 
expression. In rats housed under hypobaric atmosphere cFGF23 plasma concentration 
increased while iFGF23 concentration was unchanged, which is similar to our observations in 
SCD patients. Also cFGF23 but not iFGF23 plasma concentration was increased in women 
with iron deficiency anaemia11. All those findings suggest that tissue hypoxia secondary to 
anaemia may be the cause of the elevation of cFGF23 in SCD patients. We do not know if 
normalization of haemoglobin concentration would decrease cFGF23 concentration since 
blood transfusion does not aim at normalizing haemoglobin level in SCD patients. 
Elevated FGF23 values were not associated with modifications of phosphate or calcitriol 
levels. This finding led us to suspect that FGF23 was not intact. This was confirmed by the 
comparison of two FGF23 assays that measure either intact FGF23 or the carboxy-terminal 
fragment. This lack of correspondence between these two assays was not observed in non 
SCD-patients investigated in our department at the same time and in the same conditions as 
the SCD patients making very unlikely that the difference might be secondary to analytical 
problems. 
Our data are thus consistent with the release of cFGF23 in SCD patients. One study reported 
an increase in iFGF23 plasma concentration in SCD children with elevated serum phosphate 
concentration and normal renal phosphate excretion suggesting a renal resistance to iFGF2313. 
In rat cFGF23 can inhibit iFGF23-induced phosphaturic effect14 suggesting that a parallel 
increase in cFGF23 could explain the lack of effect of iFGF23 on phosphate excretion in 
these children. Unfortunately cFGF23 concentration was not assessed in this study. 
Our results in ARVMs confirm that cFGF23 could be responsible for the cardiac hypertrophy 
in SCD patients. While it has been demonstrated in mice and in neonate rat cardiomyocytes 
that iFGF23 can induce heart hypertrophy the effect of cFGF23 per se has never been 
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addressed. It is unknown if patients with familial calcinosis, who have elevated cFGF23 and 
low iFGF23 plasma concentrations, have cardiac hypertrophy. The present study is the first to 
provide evidence supporting a role of cFGF23 on heart. The C-terminal sequence is specific 
of FGF23, and differs from other FGFs including FGF19 and FGF2115. Our experiments 
indicate that the cFGF23 fragment by itself can increase ventricular cardiomyocyte size by 
stimulating a FGFR in the absence of αKlotho. 
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Table 1. Univariate analysis of echocardiographic parameters 
 LVMI LVEDD LVESD 
 R2  p value R2 p value R2 p value 
Age 0.031 0.1255 0.063 0.029 0.041 0.081 
Systolic blood 
pressure 
0.007 0.5471 0.04 0.147 0.003 0.691 
measured GFR  0.155 0.0004 0,131 0.0012 0.067 0.023 
PTH 0.002 0.6784 0.001 0.4124 0 0.981 
Hemoglobin levels 0.294 <0.0001 0.247 <0.0001 0.177 0.0001 
LogFGF23 0.200 <0.0001 0.106 0.0039 0.092 0.0073 
LVMI: left ventricle mass index, LVEDD: left ventricle end diastolic diameter, LVESD: left 
ventricle end systolic diameter. 
 
 
 
 
 
Table 2 Multivariate linear regression analysis of left ventricular mass index 
 β SEM p-value 
Constant 111.16 25.57 <0.0001 
haemoglobin -5.75 1.53 0.0003 
measured GFR ml/min/1.73m2 0.23 0.09 0.0110 
logcFGF23 4.96 2.36 0.0389 
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Figure Legend 
 
Figure 1: A: FGF23 concentration in patients in sickle cell disease (SCD) and controls. 
C-terminal FGF23 (cFGF23) plasma concentration is higher in SCD patients with SS (circle) 
or non- SS (diamond) genotype than in control subjects (square). cFGF23 concentration was 
natural Log-transformed to obtain normal distribution. Anova p<10-4. Differences between 
groups were analyzed with Tukey-Kramer’s test : *** p<10-4 vs. control, ### p=0.0002 SS vs. 
non-SS. B: C-terminal FGF23 (cFGF23) induces adult rat ventricular cardiomyocyte 
(ARVMs) hypertrophy. cFGF23 induces cardiomyocytes hypertrophy in a dose-dependent 
manner. cFGF23-induced cardiomyocyte hypertrophy is abolished by the FGFR inhibitor 
(PD166866). FGF2 was used as a control. ARVMs in culture were treated for 24 hours with 
cFGF23, or FGF2, or with control medium. n= 5-9 preparations. Anova p<0.0001. 
Comparison to control * p=0.005 Dunnet test. 
 
 

